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background: An enteric-coated levonorgestrel emergency contraceptive pill (E-LNG-ECP) is an improved formulation, in terms of
side effects, which both dissolves and is absorbed in the intestine. Our aim was to evaluate the efﬁcacy and safety of E-LNG-ECP as an
over-the-counter (OTC) drug for emergency contraception (EC) in Chinese women.
methods: A Phase IV clinical trial was conducted in ﬁve family planning clinics in China. Women seeking EC within 72 h after unprotected
sexual intercourse or contraceptive failure who met the inclusion criteria were recruited. The efﬁcacy of contraception (primary end-point
was pregnancy rate), side effects (i.e. safety) and the value of E-LNG-ECP for EC were investigated.
results: Of 2445 women (aged 15–48 years) who took E-LNG-ECP with follow-up to determine pregnancy, only ﬁve pregnancies
(0.2%) occurred. The efﬁcacy of contraception was 95.3%. In total, 6.5% of women reported at least one adverse event after taking E-
LNG-ECP, and no serious adverse events were reported. Only four subjects (0.16%) reported vomiting. The incidence of menstrual
cycle disturbance was 20.1% after taking E-LNG-ECP. Subjects who had previously taken ECPs (54.4% of these women) rated the accept-
ability of E-LNG-ECP at 9.36 (on a 10-point scale) higher (P , 0.05) than the rating of other LNG-EC pills taken previously.
conclusions: The study found that E-LNG-ECP was effective, safe and well tolerated as an OTC drug. However, an randomized con-
trolled trial should be performed to compare standard LNG tablets with E-LNG-ECP.
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Introduction
Emergencycontraception(EC)methods,availableinoralandintrauterine
forms, are used to prevent pregnancy after unprotected intercourse or
contraceptive failure. The most widely used EC drug is levonorgestrel
(LNG), taken orally in repeated doses (0.75 mg × 2) or as a single
dose (1.5 mg) within 72 h of sexual intercourse (Trussell et al., 2010).
LNG EC is more effective and has fewer side effects than the
Yuzpe regimen, which contains both estrogen and progestin (Cheng
et al., 2004).
Several studieshave shownthatLNG acts by inhibiting or postponing
ovulation (Gemzell-Danielsson, 2010; Leung et al., 2010; Noe ´ et al.,
2010).HigherdosesofLNGtakenafterovulation,orLNGadministered
by the vaginal route, have no effect on endometrial development or
function (Gemzell-Danielsson, 2010; Meng et al., 2010; Palomino
et al., 2010).
In recent years, the use of LNG has increased and it is now available
for women seeking EC without a doctor’s prescription in nearly 50
countries, including China (Pittrof et al., 2010; Trussell et al., 2010).
However, extensive debate on overreliance on LNG as an
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which is a barrier to switching the prescription status of LNG in
these countries. As a result, prospective, multi-center, open-label clini-
cal trials of LNG as an OTC drug are necessary to provide evidence to
inform the discussion.
The LNG emergency contraceptive pill (ECP) was approved as an
OTC drug by the State Food and Drug Administration (SFDA) in
1998 and has been widely available in China since that time. An
enteric-coated LNG-ECP (E-LNG-ECP) is an improved formulation
that both dissolves and is absorbed in the intestine rather than in
the stomach so as to reduce the adverse events of nausea and vomit-
ing. A pharmacokinetics study of E-LNG-ECP showed it to be bioequi-
valent with the previous, uncoated tablet with the use of the liquid
chromatography–tandem mass spectrometry method, although the
time to peak value in blood plasma was signiﬁcantly longer than that
for the previous tablet (Tmax: 3.4 versus 1.8 h) (Zhao et al., 2008).
We conducted a Phase IV clinical trial in Chinese women to provide
data on the efﬁcacy and safety of the E-LNG-ECP as an OTC drug.
Materials and Methods
Subjects
This study was conducted in ﬁve family-planning clinics (Shanghai,
Guangzhou, Changsha, Changchun and Wuhan) in China from
August 2009 to October 2010. Ethical approval was obtained from
the Ethics Committee of the medical college of Huazhong University
of Science and Technology. The study was performed in full compli-
ance with the Declaration of Helsinki and Good Clinical Practice of
China.
Subjects were healthy women who sought ECP to avoid unwanted
pregnancy. According to drug law and regulations in China, the
minimum number of enrolled women subjects required in a Phase
IV clinical trial of contraceptives is 2000. Given the high loss of
follow-up in clinical trials of OTC drugs (20%), we planned to
include 2400 women. Inclusion criteria were the following: 15–49
years old, regular menstrual cycle of 21–35 days, a usually menstrual
period duration of 3–7 days and seeking EC within 72 h of unpro-
tected sexual intercourse or contraceptive failure. Subjects were
excluded if they had a contraindication to LNG, chronic disease
with prolonged medication, a known or suspected pregnancy or if
they were current or recent users of hormonal methods of contracep-
tion. All participants signed informed consent forms.
Drug
The enteric-coated tablet contained 1.5 mg LNG (Nevenol
w, Regenex
Pharmaceutical Corporation, Guangzhou, China). Participants were
told to take one tablet orally within 72 h of unprotected intercourse
or contraceptive failure.
Procedures
Participants ﬁlled in a registration form to provide basic information
when they came to pharmacies to purchase emergency contracep-
tives. Throughout the study, participants were asked to keep a daily
diary to record the time of sexual intercourse and administration of
E-LNG-ECP, adverse effects, vaginal bleeding, concomitant medication
and contraceptive use. A follow-up interview (either by telephone or
in a clinic) was carried out within 3 days of the administration of
E-LNG-ECP, with the content mainly focusing on adverse events.
The second follow-up was 5–7 days after expected menses. If
menses had occurred, the follow-up study ended. Women with nega-
tive pregnancy tests without menses on the expected date were con-
tacted every 2 weeks, and periodic pregnancy testing was undertaken
until menses resumed. Positive urinary pregnancy tests were con-
ﬁrmed by measurement of serum b-hCG and later by ultrasonogra-
phy. The outcome of the pregnancies was obtained by further
follow-ups.
The primary efﬁcacy end-point was the rate of pregnancy in women
who took E-LNG-ECP within 72 h of unprotected intercourse. The
rate of side effects in women who received E-LNG-ECP within 72 h
of unprotected intercourse was analyzed as a safety measurement.
Serious side effects were deﬁned in accordance with the female har-
monization guidelines (Liao, 2004) and reported to the research
center immediately by investigators. The principal investigator
reviewed every pregnancy (enrolment and follow-up serum hCG con-
centrations, ultrasound dating, menstrual cycle and coital data) to
establish whether conception clearly occurred before E-LNG-ECP
was given or well after treatment (at least 10 days after treatment).
Pregnancies that met these criteria were deemed to be incompatible
with treatment failure. The efﬁcacy of contraception (the fraction of
expected pregnancies prevented) was estimated using the method
of Trussell et al. (1998).
In addition, the subjects who had taken ECPs in the past rated
E-LNG-ECP versus other ECPs on a scale ranging from 0 (poor) to
10 (excellent). The perceived advantages and disadvantages of
E-LNG-ECP were also investigated in the follow-up interviews of
participants.
Statistical analysis
Demographics, the efﬁcacy of contraception and the frequency of
adverse events in the observed cycle were described for the
intention-to-treat population. The data were imputed and veriﬁed in
two databases by two analyzers independently. Statistical analysis
was performed using SAS version 9.0 (Cary, NC, USA). Statistical sig-
niﬁcance was set at P , 0.05.
Results
A total of 2566 subjects were enrolled in the study, 45 of whom were
excluded because they did not meet the eligibility requirements (these
45 subjects were given E-LNG-ECP and there were no pregnancies).
A total of 2521 were therefore eligible and treated with
E-LNG-ECP; these women were all contacted for the ﬁrst follow-up
interview and were therefore included in the safety analysis. Of
these, 2445 ﬁnished the study and were included in the efﬁcacy analy-
sis, while 76 women (with characteristics similar to the others) [3.0%,
95% conﬁdence interval (CI) 2.4–3.8] were lost to follow-up (Fig. 1,
trial proﬁle). The ages of the enrolled participants ranged from 14
to 48 years, with a mean age of 27.4 years. Other characteristics of
the participants are presented in Table I. Among the 2445 subjects,
91.2% of the follow-up interviews were conducted by telephone
and 8.8% were completed in a clinic.
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A total of 2021 subjects (82.7%) had taken the E-LNG-ECP within
24 h of unprotected intercourse, 361 subjects (14.8%) within 24–
48 h and 38 (1.6%) within 48–72 h. The rest (25 women) did not
provide the speciﬁc time between coitus and drug administration.
Only ﬁve pregnancies (0.20%, 95% CI 0.07–0.48%) among 2445
women occurred during the study. Among the 2401 women who
reported the cycle day on which intercourse occurred, the expected
number of pregnancies was 106.8. The efﬁcacy of contraception was
95.3% (95% CI 88.6–98.1%). All ﬁve pregnancies ended in abortion
(four induced and one spontaneous). No ectopic pregnancy was
observed. No pregnancy was deemed incompatible with contracep-
tive failure according to the estimated date of conception.
Women lost to follow-up in our trial were 76; these were excluded
from the denominator in calculations, under the assumption that they
would experience failure at the same rate as those with observed out-
comes. If all became pregnant, the failure rate would be 3.21%. This is
considered as the highest failure rate. On the other hand, if none
became pregnant, the failure rate would be 0.20%.
Safety results
No serious adverse events were reported. Among 2521 subjects with
safety data, 178 (7.1%; 95% CI 6.1–8.1%) reported at least one
adverse event after taking E-LNG-ECP. In total, 4.2% of women
reported mild or medium nausea, which occurred usually within
60 min of treatment. The next most frequent adverse event was
vaginal bleeding and spotting (2.0%), which usually occurred within 3
days of treatment. Only four subjects (0.2%) reported vomiting, one
at 30 min after treatment and three at unspeciﬁed times. No one
took more E-LNG-ECP because of vomiting. The presence of
adverse events is detailed in Table II.
Inﬂuence on menstruation
Disturbances of the menstrual cycle were common after the
E-LNG-ECP. In total, 20.1% of women reported that their next
menses did not occur when expected, including 4.7% whose
menses started at least 7 days early and 15.4% whose menses were
delayed by .7 days. The average duration of menses was 4.9 days,
which was no different than the previous one. The menstrual bleeding
volume and the degree of dysmenorrhoea were similar to those in the
previous menstrual cycle.
Acceptability of LNG ECPs
Thousand three hundred seventy-two of 2521 women (54.4%) in this
study had used LNG ECPs previously and 99.6% obtained them from
community pharmacies. The participants’ average rating of the ECPs
used previously was 7.96 compared with 9.36 for E-LNG-ECP, a
difference that is signiﬁcant (P , 0.05), using Student t-test.
Figure 1 Proﬁle of a Phase IV clinical trial to investigate the efﬁcacy and safety of a LNG enteric-coated tablet as an OTC drug for EC.
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gated at the second follow-up. Among 2445 participants, 1363
women (55.7%) listed several advantages of E-LNG-ECP: fewer or no
side effects (52.2%), contraceptive efﬁcacy (27.7%), convenient to use
(18.0%) and attractive packaging (0.7%). Only 207 women listed some
disadvantages, which were: menses disturbance (45.9%), high cost
(42.0%), side effects (9.2%), could not frequently use (1.9%), brand
name is not well known (0.5%) and contraceptive failure (0.5%).
In addition, the subjects listed their source of ECP information at
the ﬁrst follow-up: community pharmacies (75.4%), papers or maga-
zines (24.3%), relatives or friends (10.6%), counseling by doctors
(9.6%), internet (8.3%), broadcasting (6.6%), community education
(3.3%) and others (1.3%). It was an open question and the answer
was not limited to one choice; so some women used more than
one source of information. Higher-educated women were more
likely to gain ECP knowledge from papers or magazines, broadcasting
and internet, using correlation analysis.
Contraception methods used after
E-LNG-ECP treatment
The contraception methods used after E-LNG-ECP treatment were
investigated at the ﬁrst follow-up. A total of 559 women (22.2%)
did not use any contraceptive methods after the treatment. Among
1962 women who used contraception, the methods reported were:
condoms (66.3%), ECPs (8.45%), oral contraceptive pills (1.55%),
intrauterine device (0.28%), fertility awareness methods (0.6%) and
spermicides (0.16%).
Discussion
LNG was approved as an OTC emergency contraceptive drug by
SFDA in 1998 in China and is mainly sold by community pharmacies,
which provides convenient access for women. According to the Good
Clinical Practice guidelines of SFDA, the current study was a Phase IV
clinical trial of a new tablet, E-LNG-ECP. A total of 2566 women who
were seeking ECPs from community pharmacies in ﬁve cities were
enrolled to assess the contraceptive efﬁcacy, safety and acceptability
of E-LNG-ECP. This was the ﬁrst large-sample post-marketing study
of an emergency contraceptive as an OTC drug in China.
With both the LNG and Yuzpe regimens, the earlier the treatment
begins the more effective it is. In a World Health Organization
(WHO) large randomized controlled trial (RCT) of these methods,
delaying the ﬁrst dose by 12 h increased the odds of pregnancy by
almost 50% (Piaggio et al., 1999). In our study, the contraceptive efﬁ-
cacy of E-LNG-ECP was 95.3%, and the failure rate was 0.2%, signiﬁ-
cantly lower than failure rates in the RCTs of LNG conducted by
WHO and other researchers (Ho et al., 1993; Task Force on Post-
ovulatory Methods of Fertility Regulation,1998; Piaggio et al., 1999;
Wu et al., 1999; Arowojolu et al., 2002; von Hertzen H et al.,
2002; Ngai et al., 2005) (see Supplementary data, Table SI) In our
study, 82.7% of participants took the drug during the ﬁrst 24 h after
unprotected intercourse, while only 42–46% did so in the WHO
RCT (von Hertzen H et al., 2002). Another study showed that the
failure rates of ECPs during the ﬁrst 24 h, 24–48 h and 48–72 h
were 0.4, 1.2 and 2.7%, respectively (WHO, 1998). The superior efﬁ-
cacy of E-LNG-ECP found in this study might partially be related to the
short interval between unprotected intercourse and taking the drug,
and this short interval is good evidence of the easy accessibility of
LNG ECP as an OTC drug. Subjects’ knowledge about ECP was
also helpful in reducing the time required to obtain the ECP. It
should be pointed out that the failure rates of ECPs might vary in
different studies because of differences in characteristics among
........................................................................................
Table I Baseline characteristics of participants in a
Phase IV clinical trial to study the efﬁcacy and safety of
an E-LNG-ECP as an OTC drug for emergency
contraception in China (n 5 2566).
Mean SD Range
Age (year) 27.4 6.1 14–48
Height (cm) 160.45 4.06 145–186
Weight (kg) 52.39 6.56 34.5–86
Length of menstrual cycle (days) 29.1 1.7 20–40
Duration of menstruation (days) 5.0 1.1 1–11
Marital status: total n (missing) 2410 (156) n %
Married 1075 44.61
Single 1335 55.39
Education: total n (missing) 2451(115)
Primary school or less 22 0.90
Junior high school 223 9.10
Senior high school 1258 51.33
Junior college 745 30.40
University or above 203 8.28
Contraceptive methods used recently:
total n (missing) 1749(817)
Condom 1206 50.61
Oral contraception pills 92 3.86
Emergency contraceptive 428 17.97
Other methods 23 0.91
........................................................................................
Table II Incidence of side effects after treatment with




Vaginal bleeding 51 2.02
Headache and dizziness 9 0.36
Xerostomia 8 0.32
Transient chest distress 4 0.16
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coitus and drug administration).
In our study, only 165 women (7.1%) reported a side effect, and
13 women reported more than one side effect. The presence of
side effects is lower than in previous studies, except for a similar inci-
dence of menstrual bleeding disturbances. One of the highlights in the
present study is the signiﬁcantly lower rate of nausea and vomiting
compared with that in clinical trials conducted in different reports
(WHO, 1998; Arowojolu et al., 2002; von Hertzen H et al., 2002).
Decreased nausea and vomiting are probably primarily related to
the enteric-coated tablet, which avoids irritation of the stomach. No
pregnancy was observed among subjects who vomited, but very few
vomited, precluding further investigation. Also, we could not differen-
tiate method failure from subject failure. The main reason women
chose E-LNG-ECP was that they thought it could have fewer gastro-
intestinal side effects. Therefore, the incidence of side effects, such
as nausea and vomiting, may also depend on psychological factors. If
women know that the drug is a new and improved preparation,
they may feel more reassured and be less apprehensive, which
might decrease the incidence of nausea and vomiting.
The inﬂuence of LNG on menstruation was previously found to
depend on when LNG was taken in the menstrual cycle (Raymond
et al., 2006). Taking the drug during the ﬁrst 3 weeks of one’s cycle
shortened the menstrual cycle and duration of menses, and this
effect increased when it was taken even earlier in the 3-week
period. In contrast, taking the LNG EC after ovulation had little inﬂu-
ence on menstrual cycle length or duration of menses (Tirelli et al.,
2008). In our study, nearly 80% of participants did not experience
any menstrual change during the ﬁrst cycle after treatment, while
20.1% experienced a change in timing of onset of the next menses
of .7 days. The duration and volume of menses were not affected.
The E-LNG-ECP was found to be acceptable by women in our
study. Advantages described by participants included few side
effects, satisfactory efﬁcacy and ease of use, while disadvantages
included gastrointestinal side effects (nausea), menstrual disturbance
and high cost. An estimated 19% to 22% of women were not using
any contraceptive method after ECP treatment, while another 7.5%
were relying on ECPs, which are not as effective as any ongoing
method of contraception.
The present study also investigated the accessibility of ECPs: 99.6%
of participants who had used ECPs in the past had obtained them from
community pharmacies rather than clinics. Moreover, participants’
knowledge about EC mainly came from community pharmacies
(75.4%), and only a small proportion of participants received counsel-
ing from clinicians (9.6%). The community pharmacy was not only a
place for dispensing EC pills but also an important source of infor-
mation about using the ECP correctly.
In summary, this study suggested that an LNG enteric-coated tablet
was safe and effective for use as an OTC EC drug. The E-LNG-ECP
remarkably reduced the gastrointestinal side effects, such as nausea
and vomiting. E-LNG-ECP should be available as an OTC drug in com-
munity pharmacies, while instructions on using ECPs that are dis-
pensed by pharmacists or healthcare practitioners should be
strengthened, particularly the importance of timing. Our ﬁndings
provide convincing evidence for the safety, efﬁcacy and accessibility
of ECPs in an OTC setting; however, an RCT should be performed
to compare results with the standard LNG treatment.
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